Cost effectiveness analysis of screening in the early diagnosis of prostate cancer (PCA);Untersuchungen zur kosteneffizienz von screeningmaßnahmen zur früherkennung des prostatakarzinoms: Ein überblick

Radiologe

Volumn 42, Issue 8, 2002, Pages 601-607

  Mueller Lisse, U G ^a   Mueller Lisse, U L ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cost effectiveness; Cost effectiveness analysis; Prostate; Prostate cancer; Prostate specific antigen; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; MULTICENTER STUDY; PROSTATE CANCER; PROSTATE DISEASE; BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; EUROPE; MASS SCREENING; MORTALITY; NORTH AMERICA; PROSTATE TUMOR; REVIEW; SURVIVAL;

COST-BENEFIT ANALYSIS; EUROPE; HUMANS; MALE; MASS SCREENING; NORTH AMERICA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036691479     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-002-0779-1     Document Type: Article

References (22)

1. American Cancer Society (2002) Cancer facts and figures.www.cancer.org
2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E (1987) Prostate-specific antigen as serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916
3. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al. (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161
4. Littrup PJ (1997) Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society. Cancer 80:1864-1870
5. Holmberg H, Carlsson P, Löfman O, Varenhorst E (1998) Economic evaluation of screening for prostate cancer: a randomized population based program during a 10-year period in Sweden. Health Policy 45:133-147
6. Varenhorst E, Carlsson P, Capik E, Lofman O, Pedersen KV (1992) Repeated screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Acta Oncol 31:815-821
7. Krahn MD et al. (1999) Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen. CMAJ 160:49-57
8. Miller AB, Madalinska JB, Church T, Crawford D, Essink-Bot ML, Goel V, de Koning HJ, Määttänen L, Pentikäinen T (2001) Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US prostate, lung, colon and ovary trial. Eur J Cancer 37:2154-2160
9. Perez-Niddam K, Thoral F, Charvet-Protat S (1999) Economic evaluation of a prostate cancer screening program in France: a decision model. Crit Rev Oncol Hematol 32:167-173
10. Krahn MD et al. (1994) Screening for prostate cancer. A decision analytic view. JAMA 272:773-780
11. Gustafsson O et al. (1995) Cost-effectiveness analysis in early detection of prostate cancer: an evaluation of six screening strategies in a randomly selected population of 2,400 men. Prostate 26:299-309
12. Trinkler FB (1995) Screening of prostate carcinoma. Ther Umsch 52:393-398
13. Madalinksa JB, Essink-Bot ML, de Koning HJ et al. (2001) Health related quality of life effects in patients with screen-detected versus clinically diagnosed prostate cancer proceeding primary treatment. Prostate 46:87-97
14. Beemsterboer PMM, de Koning HJ, Birnie E et al. (1999) Advanced prostate cancer: course, care, and cost implications. Prostate 40:97-104
15. Candas B et al. (2000) Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate 45:19-35
16. Ross KS et al. (2000) Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 284:1399-1405
17. Zappa M et al. (1998) Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 9:1297-1300
18. Imai K, Fukabori Y, Yamanaka H (1996) Etiology of prostate cancer and significance of screening for early prostate cancer. Gan To Kagaku Ryoho 23:403-406
19. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D (1997) Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1:1-96
20. Benoit RM, Naslund MJ (1997) The economics of prostate cancer screening. Oncology (Huntington) 11:1533-1543
21. Littrup PJ et al. (1994) Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society - National Prostate Cancer Detection Project. J Urol 152 (5 PT 2):1873-1877
22. Mangin P et al. (1998) Should we screen for pro-state cancer? Ann Urol (Paris) 32:63-67